EZZ Reports 25% Drop in Q3 Receipts, Signs $10 Million Distribution Pact

Softer E-Commerce Demand Hits Q3 Receipts

EZZ Life Science Holdings (ASX:EZZ) saw customer receipts slide 25% to $8.85 million in Q3 FY26, reflecting weaker consumer engagement across several key e-commerce platforms. While JD Health's channels surged by over 90%, this was offset by declines on Douyin, Kuaishou, and Tmall, where competition from cheaper unbranded products intensified. The mixed channel performance underscores the challenges premium health brands face in crowded digital marketplaces.

$10 Million Global Distribution Pact with Aumake

Amid this backdrop, EZZ inked a four-year exclusive global distribution agreement with Aumake Limited, locking in minimum purchase commitments of $10 million over the term, including $2.5 million annually. This deal appoints Aumake as the sole global distributor for a range of co-developed EZZ-branded products, aligning with EZZ's strategy to amplify its international footprint while retaining control over branding and quality. The agreement builds on earlier announcements about the partnership and represents a critical pillar in EZZ's scaling ambitions four-year exclusive global distribution agreement.

Strengthening China Market Presence with JD Health

Furthering its China strategy, EZZ established a strategic cooperation framework with JD Health, a leading online healthcare platform. This partnership aims to enhance omnichannel execution and bolster brand positioning in one of the most competitive health product markets globally. The focus on premium branding through JD Health contrasts with the challenges faced on other Chinese e-commerce platforms and reflects a nuanced approach to market segmentation and consumer targeting.

Product Innovation and Domestic Expansion

EZZ launched the MeTime Series, a collection of four new health supplements targeting hormone balance, sleep, muscle relief, and mobility. Alongside these, the company upgraded its flagship Daily Energy & Wellbeing Pro formulation and introduced a children’s product tailored for the China market, EZZ Kidztech Lactic Acid Bacteria Pressed Candy. Domestically, EZZ expanded its pharmacy distribution network, enhancing accessibility across Australia and New Zealand. These moves follow a broader trend of product innovation and channel diversification seen in prior quarters Q1 sales dip and new product launches.

Governance Enhancements Support Growth

On the governance front, EZZ bolstered its board with the appointments of Executive Director Christine Chen and Non-Executive Director Janice Hsu in January 2026, alongside Gary Liu as Non-Executive Chair. These changes aim to strengthen oversight and support the company’s international growth trajectory, signaling a maturing governance framework as EZZ scales operations.

Cash Position and Financial Flexibility

Despite the softer sales, EZZ maintained a healthy cash balance of $9.96 million at quarter-end, remaining debt-free excluding lease liabilities. The net operating cash outflow of $3.2 million was driven by lower receipts and ongoing investments in inventory, marketing, and strategic initiatives. This cash buffer provides a runway of approximately three quarters at current burn rates, allowing the company to continue executing its growth plans without immediate liquidity pressure.